AbstractAbstractInternational Journal of Pharmacology and Clinical Sciences,2023,12,3,138-139.DOI:10.5530/ijpcs.2023.12.17Published:February 2024Type:Research ArticleAuthors:Juman Alsaab Author(s) affiliations:Juman Alsaab, Pharm D Ministry of Health, Riyadh, SAUDI ARABIA. Abstract:Registrations: It had been registered in the following countries: United Kingdom (UK), United States of America (USA), Canada, and Saudi Arabia (SA). Trade name (USA.); TERLIVAZ ® Registration number (SA); 11-367-07. Insurance Drug Formulary (SA); Covered. General Information: Registered Company: Mallinckrodt hospital products inc. Regulatory Status: RX. Mechanism of Action: Prodrug The active form is lysine vasopressin, the non-selective agonist of both V1 (smooth muscles of the arterial vasculature in the splanchnic region) and V2 receptors (collecting ducts of renal tubules). Read more... View:PDF (162.2 KB) PDFClick here to download the PDF file. Images emailfacebooklinkedintwittergoogle+pinterest ‹ Pharmacy Safety and Occupational Health: Crisis and Disaster Management up Advanced Practice of Total Parenteral Nutrition by Physicians in Saudi Arabia ›